Inactive Instrument
Company Progenics Pharmaceuticals, Inc.
Stocks
US7431871067
Biotechnology & Medical Research
Business description: Progenics Pharmaceuticals, Inc.
Sales by Activity: Progenics Pharmaceuticals, Inc.
| Fiscal Period: December | 2019 (USD) |
|---|---|
Pharmaceuticals | 34.99M |
Executive Committee: Progenics Pharmaceuticals, Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
David Mims
CEO | Chief Executive Officer | 62 | - |
Company details: Progenics Pharmaceuticals, Inc.
Bio Therapeutic Drugs
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.03% | +0.40% | +57.52% | +108.61% | 54.92B | |
| -0.34% | +3.51% | +45.55% | +40.16% | 44.31B | |
| +0.29% | +6.20% | -14.80% | -19.65% | 22.96B | |
| -0.40% | +3.49% | -1.29% | +387.06% | 21.12B | |
| -3.17% | 0.00% | +12.98% | -36.90% | 16.31B | |
| -1.30% | -1.83% | +7.22% | -40.94% | 15.19B | |
| -0.24% | +2.44% | +27.43% | +177.49% | 13.32B | |
| +0.91% | +9.19% | +18.62% | - | 12.48B | |
| +0.32% | +2.81% | +96.37% | +213.49% | 11.21B | |
| Average | -0.44% | +2.75% | +27.74% | +103.66% | 23.54B | |
| Weighted average by Cap. | -0.37% | +2.86% | +32.15% | +95.33% |
